This disclosure relates to a crystal of 3-{4-[(2R)-2-aminopropoxy]phenyl}-N-[(1R)-1-(3-fluorophenyl)ethyl]imidazo[1,2-b]pyridazin-6-amine adipate.

The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical compositions comprising the salts and solid forms and to use of said compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.

The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical compositions comprising the salts and solid forms and to use of said compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.

Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

The present invention relates to a method of producing adipic acid, including a step (hydrogenation step) of reacting 3-hydroxyadipic acid-3,6-lactone with hydrogen in an aqueous solvent in a presence of a hydrogenation catalyst. The hydrogenation catalyst preferably includes one kind or two or more kinds of transition metal elements selected from the group consisting of palladium, platinum, ruthenium, rhodium, rhenium, nickel, cobalt, iron, iridium, osmium, copper, and chromium.

The present invention relates to a method of producing adipic acid, including a step (hydrogenation step) of reacting 3-hydroxyadipic acid-3,6-lactone with hydrogen in an aqueous solvent in a presence of a hydrogenation catalyst. The hydrogenation catalyst preferably includes one kind or two or more kinds of transition metal elements selected from the group consisting of palladium, platinum, ruthenium, rhodium, rhenium, nickel, cobalt, iron, iridium, osmium, copper, and chromium.

Crystalline forms of upadacitinib and processes for preparation thereof are disclosed. The present disclosure also relates to pharmaceutical compositions containing the upadacitinib crystalline forms, use of the upadacitinib crystalline forms for preparing JAK1 inhibitor drugs, and use of the upadacitinib crystalline forms for preparing drugs treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis and psoriatic arthritis. The crystalline forms of upadacitinib provided by the present disclosure have one or more improved properties compared with prior arts and have significant values for future drug optimization and development. ##STR00001##

The present invention disclosed a single step process for the conversion of cyclohexane to adipic acid by using manganese oxide, tungsten oxide or Mn—WOx nano structure having improved yield and selectivity.

The present invention disclosed a single step process for the conversion of cyclohexane to adipic acid by using manganese oxide, tungsten oxide or Mn—WOx nano structure having improved yield and selectivity.

The present invention disclosed a single step process for the conversion of cyclohexane to adipic acid by using manganese oxide, tungsten oxide or Mn—WOx nano structure having improved yield and selectivity.